Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

"With the divesture of YUSIMRY, Coherus reinforces its strategic focus on oncology," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "The proceeds from the sale of YUSIMRY will bolster our cash position, advance our efforts to become a sustainable and growing oncology company and efficiently allocate our resources for maximum value creation." Latham & Watkins LLP provided Coherus with legal counsel regarding the transaction. Coherus' immuno-oncology pipeline includes multiple antibody immu ...